Background Patients with heart failure (HF) frequently suffer from undetected declines in cardiorespiratory fitness (CRF), which significantly increases their risk of poor outcomes. However, current ...

Arrowhead Pharmaceuticals (ARWR) reported a robust start to fiscal year 2026, significantly surpassing earnings expectations. The company posted an EPS of $0.22, compared to the forecasted $0.12, ...

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. [Operator Instructions] I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations for ...